MLYS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ML

Mkt Cap

$1.80B

Volume

998.39K

Next Earnings

November 9th

Loading chart

ML

MLYSMineralys Therapeutics, Inc. Common Stock

MLYS

Pay with—

Available Balance0.00

ML

Mkt Cap

$1.79B

Volume

998.39K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices.GlobeNewswire Inc. · Oct 9, 2026

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026Mineralys Therapeutics announced that new data from the Launch-HTN Phase 3 clinical trial of lorundrostat, an investigational aldosterone synthase inhibitor, will be presented at the American Society of Nephrology Kidney Week 2026. The presentation will focus on blood pressure and albuminuria reduction in chronic kidney disease patients. Lorundrostat is being developed to treat uncontrolled and resistant hypertension, with the company having completed six late-stage clinical trials demonstrating efficacy and safety.GlobeNewswire Inc. · Oct 2, 2026

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.GlobeNewswire Inc. · Sep 16, 2026

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)Mineralys Therapeutics announced that late-breaking data from a proteomic analysis of heart failure biomarkers during lorundrostat treatment will be presented at ENDO 2026. The data comes from post hoc analysis of the Launch-HTN and Advance-HTN trials, which evaluated the aldosterone synthase inhibitor for treating uncontrolled and resistant hypertension.GlobeNewswire Inc. · Jun 8, 2026

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent FinancingMineralys Therapeutics announced the repurchase of all future royalty payments to Tanabe Pharma for lorundrostat, paying $200 million upfront plus up to $100 million upon commercial milestones. Concurrently, the company secured a $500 million senior secured term loan facility from Pharmakon Advisors and priced a $150 million common stock offering to strengthen its balance sheet.GlobeNewswire Inc. · Jun 3, 2026

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionVelan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.The Motley Fool · May 31, 2026

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)Mineralys Therapeutics presented post hoc analysis data from its Phase 3 Launch-HTN trial showing that lorundrostat, an aldosterone synthase inhibitor, achieved statistically significant blood pressure reductions in patients with chronic kidney disease (CKD) and hypertension. The drug demonstrated a 9.6 mmHg placebo-adjusted systolic blood pressure reduction in CKD patients and a 52.2% reduction in urinary albumin-to-creatinine ratio in those with baseline albuminuria, with a favorable safety profile. The drug is currently under FDA review with a PDUFA target date of December 22, 2026.GlobeNewswire Inc. · May 30, 2026

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, demonstrating promising results in reducing blood pressure and albuminuria in chronic kidney disease patients. The company plans to file a New Drug Application with the FDA in late 2025 or early 2026.GlobeNewswire Inc. · Nov 7, 2025

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street AnalystsTwo healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.The Motley Fool · Sep 7, 2025

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical NeedMineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.GlobeNewswire Inc. · Sep 5, 2025

to start trading

ML

MLYSMineralys Therapeutics, Inc. Common Stock

MLYS

Pay with—

Available Balance0.00

Your PositionYou don't own any MLYS yet.

Related Tickers

Earnings